# Maple Syrup Urine Disease Caused by a Partial Deletion in the Inner E<sub>2</sub> Core Domain of the Branched Chain $\alpha$ -Keto Acid Dehydrogenase Complex due to Aberrant Splicing

A Single Base Deletion at a 5'-Splice Donor Site of an Intron of the  $E_2$  Gene Disrupts the Consensus Sequence in This Region

Hiroshi Mitsubuchi, Yoshitaka Nobukuni, Izumi Akaboshi, Yasuhiro Indo, Fumio Endo, and Ichiro Matsuda Department of Pediatrics, Kumamoto University Medical School, Kumamoto 860, Japan

#### Abstract

We have studied the molecular bases of maple syrup urine disease by analyzing the activity, subunit structure, mRNA sequence, and the genome of the affected enzyme. The branched chain  $\alpha$ -keto acid dehydrogenase (BCKDH) activity in the patient was 4.2-4.5% of the control level. Immunoblot analysis revealed that the E<sub>2</sub> subunit of BCKDH (M, 52,000) was absent and another protein band with an M, of 49,000 was present. We amplified the cDNA of the E<sub>2</sub> subunit obtained from the patient's cell using the polymerase chain reaction method, then sequenced the amplified cDNA, in which a 78-bp deletion was identified. The consanguineous parents and a sister had two species of mRNA; the one corresponding to the normal  $E_2$ subunit and the other with a 78-bp deletion, whereas findings in a brother were normal. The molecular size of the translation products as deduced from the abnormal mRNA sequence was compatible with an abnormal protein band (M, 49,000) detected in the patient's cells by immunoblot analysis.

Analysis of genomic DNA of BCKDH- $E_2$  subunit revealed that the 78-bp deletion in the mRNA was caused by an exon skipping due to a single base deletion in the 5'-splice donor site. As a result of the mutation, part of the inner  $E_2$  core domain was omitted. The specified region of the inner  $E_2$  core domain was highly homologous to the region of the  $E_2$  subunit of pyruvate dehydrogenase and  $\alpha$ -ketoglutalate dehydrogenase. These observations imply the biological importance of the region in the inner  $E_2$  core domain of BCKDH to maintain normal function of the activity. (*J. Clin. Invest.* 1991. 87:1207–1211.) Key words: inherited metabolic disease  $\bullet$  branched chain amino acid  $\bullet$  polymerase chain reaction  $\bullet$  mRNA  $\bullet$  mutation

### Introduction

Branched chain  $\alpha$ -keto acid dehydrogenase (BCKDH)<sup>1</sup> is a multienzyme complex associated with the mitochondrial inner

Address reprint requests to Dr. Ichiro Matsuda, Department of Pediatrics, Kumamoto University Medical School, Honjo 1-1-1, Kumamoto 860, Japan.

Received for publication 30 May 1990 and in revised form 1 October 1990.

J. Clin. Invest.

membrane and catalyzes oxidative decarboxylation of the  $\alpha$ keto acids derived from transamination of the branched chain amino acids, valine, leucine, and isoleucine. The BCKDH consists of three catalytic components; a branched chain  $\alpha$ -keto acid decarboxylase  $(E_1)$ , a dihydrolipoyl transacylase  $(E_2)$ , and dihydrolipoamide dehydrogenase  $(E_3)(1-4)$ . The enzyme complex also contains two regulatory enzymes, a specific kinase (5-7) and a specific phosphatase (8, 9) that regulates the enzyme activity by phosphorylation–dephosphorylation. The  $E_2$ subunits form the structural core of the enzyme, to which  $E_1$ ,  $E_3$ , the kinase, and the phosphatase are attached through noncovalent interactions (1, 8, 10). The E<sub>2</sub> subunit has three domain structures; lipoyl-bearing, E3-binding, and inner core domains. The last domain has the transacylase active site and comprises the carboxy-terminal half of the E<sub>2</sub> polypeptide, assembling into a 24 mer (11).

Impaired BCKDH activity leads to maple syrup urine disease (MSUD) (12). We (13, 14) and others (15) reported that some patients with MSUD showed decreased amounts of  $E_2$ protein. To investigate related molecular mechanisms, we and others isolated a cDNA clone encoding the entire  $E_2$  subunit of the human BCKDH complex (16, 17).

We now report our analysis of a classical case of MSUD, in terms of the activity, subunit structure, mRNA sequence, and genomic sequence of BCKDH. We used the polymerase chain reaction (PCR) to amplify  $E_2$ -specific sequences from total RNA and genomic DNA isolated from EB-transformed lymphoblastoid cells derived from an MSUD patient with an abnormal  $E_2$ -like protein, detected using immunoblots. Part of the inner core domain of  $E_2$  lacking in the patient was caused by a deletion of a single guanine at the exon-intron splice junction.

# Methods

*Cell lines.* Lymphoblastoid cell lines were established by Epstein-Barr virus-mediated transformation of peripheral blood B lymphocytes from the patient (18). Studies were done on peripheral leukocytes taken from 10 ml of (heparinized) blood from the family members. Cell line GM 1366 was obtained from the Human Mutant Cell Repository, Camden, NJ.

*Enzyme assay.* Substrate-dependent kinetics of the BCKDH was determined for disrupted lymphoblastoid cells by quantifying the  $^{14}CO_2$  released from  $\alpha$ -keto [1- $^{14}C$ ] isovaleric acid, in the presence of co-factors, as described (13, 14).

Immunoblot analysis. Mitochondrial proteins were resolved by electrophoresis in a 10% polyacrylamide gel in the presence of SDS essentially as described by Laemmli (19). The resolved proteins were electroblotted to nitrocellulose and cross-reacting proteins were detected using affinity-purified anti-bovine BCKDH ( $E_1 + E_2$ ) rabbit immunoglobulin, as described (13, 14).

<sup>1.</sup> Abbreviations used in this paper: BCKDH, branched chain  $\alpha$ -keto acid dehydrogenase; E<sub>1</sub>, branched chain  $\alpha$ -keto acid decarboxylase; E<sub>2</sub>, dihydrolipoyl transacylase; E<sub>3</sub>, dihydrolipoamide dehydrogenase; MSUD, maple syrup urine disease; PCR, polymerase chain reaction.

<sup>©</sup> The American Society for Clinical Investigation, Inc. 0021-9738/91/04/1207/05 \$2.00 Volume 87, April 1991, 1207-1211

Analysis of cDNA. Total RNA was isolated from cultured lymphoblastoid cells of the patient and from the peripheral leukocytes of family members, as described (20). First-strand cDNAs were generated from 30 µg of total RNA, using Moloney murine leukemia virus reverse transcriptase (Bethesda Research Laboratories, Gaithersburg, MD) in 50 mM Tris-HCl (pH 8.3), 40 mM KCl, one mM DTT, 6 mM MgCl<sub>2</sub>, and 0.5 mM dNTPs (dATP, dCTP, dGTP, and dTTP) with specific antisense oligonucleotides primers; 5'-TGAACATGTGCT-GGCACAGCTAGGGT-3'. The cDNAs were then subjected to 40 cycles of enzymatic amplification (21). The two sets of sense/antisense oligonucleotides were designed to cover the entire normal human cDNA sequence: 5'-GGCTGCAGTCCGTATGCTGAGAACCT-3'/5'-ATGAGGTATCTTCAGGGCTGCAGACA-3', and 5'-AATGGT-CAAGACTATGTCTGCAGCCC - 3' / 5' - GGGAGCTCAAAAAGT-TCAAGAATGTC-3' (16). The amplified cDNAs were subcloned into the multicloning site of a plasmid vector pUC18, and four independent clones of each amplified cDNA segment were sequenced using a Sequenase kit (United States Biochemical Corp., Cleveland, OH).

Analysis of genomic DNA. A human genomic DNA library was screened for clones carrying the BCKDH E<sub>2</sub> subunit gene, using the plaque hybridization technique (22). The library was constructed from Sau 3A partial digests of human leukocytes DNA (a kind gift from Dr. M. Mori, Kumamoto University). Approximately  $1 \times 10^6$  EMBL 4 phages of total DNA library were screened, using the human BCKDH E<sub>2</sub> subunit cDNA insert as a probe. Phage DNAs of positive clones were characterized by restriction mapping and Southern hybridization analysis. Subclones were constructed with plasmid pUC18 as a vector, and the nucleotide sequences were determined. Genomic DNA for analysis was purified from cultured lymphoblastoid cells according to Maniatis et al. (22), but with some modification. The specific amplification of a genomic region that included an exon corresponding to the deletion in the mRNA of BCKDH-E<sub>2</sub> subunit in the patient was attempted with oligonucleotide A and B as primers (see Fig. 5). Primer A (5'-CAT-TGGCAGTAATGTGAC-3') is complementary to the antisense DNA strand of the intron, 141-158 nucleotides upstream of the exon. Primer B (5'-GGTACAATAGAAGTCTCT-3') is complementary to the sense DNA strand of the intron, 67-84 nucleotides downstream of the exon. The amplified DNAs were subcloned into the multicloning site of pUC18, and four independent clones of each amplified DNA segment were sequenced.

Clinical features of the MSUD patient. The patient T.H. (female) was the progeny of second cousin parents. A severe ketoacidosis associated with convulsion and unconsciousness occurred on the 10th postnatal day. Elevated levels of blood leucine became apparent at 11 d of age and exchange transfusion and peritoneal dialysis were initiated. After this treatment, she was put on a diet restricted for protein and branched chain amino acids (400–500 mg/d as leucine). Under these conditions, she experienced frequent attacks of severe ketoacidosis for the next 5 yr, and the attacks were usually preceded by an infection. The clinical phenotype was categorized as a classical case of MSUD.

## Results

The disrupted normal lymphoblastoid cells showed a hyperbolic Michaelis-Menten kinetics over the substrate range tested, 0.05-1.0 mM. The  $V_{max}$  and apparent  $K_m$  values were 13-15 nmol/h per milligram of protein and 0.053-0.056 mM, respectively. Cells from the patient (T.H.) showed a significantly reduced enzyme activity, in that the  $V_{max}$  and apparent  $K_m$  in the patient were 1.2 nmol/h per milligram of protein and 0.103 mM, respectively. Another cell strain related to E<sub>2</sub> deficiency (GM 1366) was analyzed as a reference (13, 14) (Fig. 1).

Immunoblot analysis of BCKDH revealed that three main immunogenic peptides, the E<sub>2</sub> ( $M_r$  52,000), E<sub>1</sub> $\alpha$  ( $M_r$  46,000), and E<sub>1</sub> $\beta$  ( $M_r$  37,000) were present in the normal control (lane 1). In the two samples (GM 1366 in lane 2 and patient T.H. in



Figure 1. Activities of BCKDH and immunoblot analysis of BCKDH proteins in disrupted lymphoblastoid cells from disease-free and MSUD subjects. The rate of the overall reaction catalyzed by the multienzyme complex was measured as described in Methods. The cell lines from disease-free and MSUD subjects are: control 1 (•); control 2 ( $\odot$ ); the patient (T.H.) ( $\blacktriangle$ ); and GM 1366 (•). BCKDH immunoreactive proteins were detected by the immunoblot technique, using affinity-purified antibody. The BCKDH (E<sub>1</sub> + E<sub>2</sub>) peptides were, in decreasing size: E<sub>2</sub>, dihydrolipoyl transacylase ( $M_r$  52,000); E<sub>1</sub> $\alpha$ , the  $\alpha$ -subunit of branched-chain  $\alpha$ -keto acid decarboxylase ( $M_r$  46,000); E<sub>1</sub> $\beta$ , the  $\beta$  subunit of branched-chain  $\alpha$ -keto acid decarboxylase ( $M_r$  37,000). (Lane 1) Disease-free cell line (control 1); (lane 2) MSUD patient (GM 1366); (lane 3) a cell line from MSUD patient (T.H.). The arrow indicates the abnormal protein band.

lane 3), the  $E_2$  subunits ( $M_r$  52,000) were absent and a protein band ( $M_r$  49,000) was present in the latter sample (lane 3, *arrow*).

To define the gene mutation in the patient (T.H.), we cloned and sequenced the cDNA of the  $E_2$  subunit of BCKDH by reverse transcription of RNA followed by PCR. Two sets of sense-antisense primers were designed, based on the normal human BCKDH- $E_2$  cDNA sequence (Fig. 2). Thus, the complete coding region of the mature BCKDH- $E_2$  was amplified as overlapping two segments, and these were subcloned into pUC18 for DNA sequencing.

The amplified segment corresponding to the 5' region of cDNA was within a normal length and there was no change in the nucleotide sequence. Another amplified segment corresponding to the 3' region of cDNA was shorter than the normal one. We found a 78-bp in-frame deletion in the cDNA sequence, as shown in Fig. 3 *a*. The abnormal cDNA encoded 451 amino acids with the lack of the 26 amino acids inner  $E_2$  core domain (Fig. 3 *b*).

The molecular size of the translation products deduced from the abnormal mRNA sequence was compatible with the



Figure 2. A feature of the human  $BCKDH-E_2$  subunit precursor cDNA and locations of the primary PCR primers. The open box and the line depict coding and noncoding regions, respectively. Restriction sites are indicated above the cDNA. Restriction enzymes used were: HindIII (H); KpnI (K); and PstI (P). The white arrow indicates the orientation and the region of primer used for the synthesis of the first strand cDNA. The solid arrows indicate the orientation and the region. (a) Segment of 5' region. (b) Segment of 3' region.



MUTANT SerPheMetProPhePheLeuLysAlaSerHisAsnIleGlyIleAla

Figure 3. (a) Sequence analysis of cDNAs synthesized and amplified from RNAs obtained from cultured cells from the patient and the control. The results of nucleotide sequencing of the normal cDNA and the mutant cDNA are shown. The 78-bp deletion was present in the patient. The base numbers for the breakpoints are indicated. (b) Amino acid sequence of a region of  $E_2$  of normal and mutant proteins predicted from the cDNA sequences. In-frame deletion of 78 bp resulted in elimination of 26 amino acid residues from the normal sequence in the mutant  $E_2$ . abnormal protein band ( $M_r$  49,000) found in the patient's cells by immunoblot analysis. To demonstrate that this change was not due to an amplification or cloning artifact, the PCR of this region was repeated four times with different batches of cDNA prepared from total RNA of EB-transformed lymphoblastoid cells and peripheral leukocytes from the patient; the deletion appeared in all cases. PCR amplification of the segment of 3' region of the cDNA from the family members was done similarly; the PCR products were digested with PstI-KpnI and hybridized with the normal cDNA sequence.

As shown in Fig. 4, the parents had two species of cDNA fragments, one with a smaller size that was compatible with the abnormal mRNA with a deletion of 78 nucleotides, and one with a normal size. Only the brother carried the fragment of a normal size. The sister had two fragments, one normal and one the mutant cDNA, similar to findings in the parents. These data indicated that the parents and sister were heterozygotes for the mutant allele and normal allele, and the brother as a homozygote for the normal allele.

To examine the putative mutation in the  $E_2$  gene, Southern blot analysis was made of the genomic DNA. Genomic DNA from the patient was digested with five different restriction enzymes (EcoRI, BamHI, HindIII, KpnI, and PstI) and probed with a KpnI–PstI restricted cDNA fragment, including the region of the deletion. No major rearrangement of the gene was detected (data not shown).

We then attempted to isolate genomic DNA fragments containing the nucleotide sequence deleted from the mRNA. The exon related to the deletion was identified by Southern blot analysis of the phage DNAs, using cDNA fragments obtained from the control and from the patient. A 0.6-kb EcoRI fragment that gave a positive signal with the normal cDNA and a negative signal with the abnormal cDNA was identified and was subcloned into a plasmid pUC18, and the nucleotide sequence determined. The EcoRI fragment from the genomic library contained a single exon composed of the 78 bp deleted from the mRNA. A part of the nucleotide sequence is shown in Fig. 5. The results of Southern blot analysis and the sequencing



Figure 4. Partial pedigree of the family and PCR analysis of the cDNA. All samples were amplified by PCR for the segment of the 3' region of cDNA. PCR products were digested with PstI-KpnI and hybridized with a 413-bp, PstI-KpnI fragment derived from normal sequence cDNA. This fragment includes the region of the 78-bp deletion. Fragment sizes (bp) are indicated. (1) Father; (2) mother; (3) brother; (4) sister; (5) proband; (6) control.

-150	-140	-130	-120	-110
CATTGGCAGTAA	TGTGACTAGG	TACATGTAGA	CTTGAAATTA	AACTCAGC
primer	A			
-100	-90	-80	-70	-60
ATAAATAAGAGI	TCTCTCTCTC	CCTCCTTTTA	TACCTCTTAT	TGTTTCAA
-50	-40	-30	-20	-10
ATTCTCTATCCI	TTCTAAGTTA	AAAGTACTAA	AATTGCATTC	TTTTTCTG
1	10	20	30	40
TTAAACAGGCTG	CTTCCTTGGG	ATTACTACCA	TTTCCTATCC	TTAACGCT
AlaA	laSerLeuGl	yLeuLeuPro	PheProIleL	euAsnAla
50	60	70	80	90
TCTGTGGATGAA	AACTGCCAGA	ATATAACATA	TAAGGTTGGC	TATGCAGA
SerValAspGlu	AsnCysGlnA	snIleThrTy	rLys	
100	110	120	130	140
GTAAAAATGTTC	TTATTATTA	TAGAAGATGG	GGCAAATGTG	CTTGTAGA
150	160	170	180	190
TTAGAGACTTCI	ATTGTACCTC	AAATAGTGAT	CTTTTTTAGA	CTAGAATT
primer B				

Figure 5. DNA sequence around the exon deleted in the mRNA in the patient. The exons were boxed and deduced amino acids are indicated under the nucleotide sequence. The nucleotide corresponding to the 5' end of the exon was numbered 1. The exon was composed from 78-bp nucleotides corresponding to the deletion in the mRNA. The arrows indicate the location of primers for PCR amplification. Fragments of 320-bp nucleotides that covered the exon were amplified with primers A and B by PCR.

of the genomic DNA strongly suggest that the mutation in the patient was related to the splicing of mRNA.

Based on the nucleotide sequence of the introns on the boundary of the exon, we prepared a set of oligonucleotide to amplify the region of the genomic DNA in order to investigate the structure of the gene in the patients (Fig. 5). A DNA fragment of 320 bp was amplified and the amplified DNAs were subcloned and sequenced. The results of the nucleotide sequencing are shown in Fig. 6 a. A single guanine from the exon-intron junction was missing in the patient. This mutation did not disrupt the doublet of GT at the 5' end of the intron; however, the consensus sequence of AAGGT (23) was changed to AAGT (Fig. 6 b).

## Discussion

The patient with a classical type of MSUD caused by a deficiency of BCKDH- $E_2$  subunit was found to have a 78-bp deletion in the mRNA of the BCKDH- $E_2$  subunit. The sequence of the mutated cDNA revealed that the deletion occurred between homologous regions in the cDNA sequences. Therefore, first we speculated that the homologous recombination or slipped mispairing in the region of the  $E_2$  gene seemed to be involved in the putative mutation in the patient (24–26).

Southern blot analysis of the genomic DNA from the patient revealed no major rearrangement in the  $E_2$  gene. For further analysis of gene mutation, we cloned genomic DNAs covering the deleted cDNA sequence, since the structure of the  $E_2$ gene had to be determined.

An exon containing the nucleotide sequence that was deleted in the mRNA of the patient was identified and cloned (by PCR) from the genomic DNA of the patient and the controls. The sequencing of the cloned DNA from the patient revealed a deletion of guanine at the consensus splice site sequence of AAGgt at 5' end of the intron (Fig. 6 b). This region is involved in binding of Ul small nuclear ribonucleoprotein particles and undergoes cleavage in the spliceosome and lariat formation (27). As a result of the mutation, abnormal splicing (exon skipping) of the mRNA occurred and an entire exon of 78 bp was deleted in the mRNA.



Figure 6. (a) Sequence analysis of amplified genomic DNAs obtained from cultured cells from the patient and the control. A single base deletion of G at the 5' splice donor site is shown. The arrow indicates the exon intron splice junction. (b) Comparison of the nucleotide sequences of the mutant, normal, and the consensus sequence for 5' splice donor site. The sequence in the normal sequence AAGGT was identical to that of the consensus sequence.

Exon skipping due to a point mutation of 5'-splice donor site has been reported (28-30). Among those single nucleotide substitutions of the dinucleotide of gt at the 5'-splice donor site were usual cases of the abnormal splicing. A unique feature in our mutation was that the dinucleotide of gt consensus sequence was apparently conserved in this particular region of the human  $E_2$  gene. This type of mutation has not been linked as a cause of genetic disorders.

Mutation in the gene resulted in synthesis of abnormal mRNA; subsequently, a mutant subunit of  $E_2$  was synthesized and possibly incorporated into mitochondria accompanying the normal  $E_1$  and  $E_3$  subunits of BCKDH.

The  $E_2$  subunits form the structural core of the enzyme, to which  $E_1$ ,  $E_3$ , the kinase, and the phosphatase are attached through noncovalent interactions (1, 8, 10). The E<sub>2</sub> subunit has three domain structures; lipoyl-bearing, E<sub>3</sub>-binding, and inner core domains. The last domain has the transacylase active site (11). The deduced amino acid sequence from the mutated cDNA revealed that the mutant  $E_2$  peptide in the patient, which was weakly visible on the immunoblot, lacks 26 amino acids (Nos. 253-278) in the inner core domain. The BCKDH activity in the patient was decreased to the level seen in another patient with E<sub>2</sub> deficiency (GM 1366), for whom there was no cross-reactive material in the immunoblot. The amount of the mutant  $E_2$  subunit seemed to be decreased in the present patient. Possible interpretations are a decreased synthesis in abnormal mRNA, an impaired incorporation of the precursor protein into mitochondria, or a decrease in the stability of the mutant protein.



Figure 7. Schematic comparison of domain structures of normal and the mutant  $E_2$  of BCKDH. Open boxes represent the putative leader peptide, lipoyl bearing domain,  $E_3$  binding domain, and inner core domain with the CoA-SH binding site. The solid box represents the region of the deletion in the inner core domain in the patient. K indicates the position of the lipoyllysin residue.

The specific region of the inner  $E_2$  core domain indicates a strong species conservation and is highly homologous to the region of  $E_2$  subunit of pyruvate dehydrogenase, and that of  $\alpha$ -ketoglutarate dehydrogenase (16, 17). The region in the inner  $E_2$  core domain of BCKDH, which is deleted in our patient, seems biologically important to maintain normal functions of the subunit protein. This deletion would explain the grossly altered active site of the  $E_2$  subunit (Fig. 7).

Deletion in the mRNA in her family was identified by PCR. The mother, the father, and the sister had two species of mRNA; the one corresponding to the normal  $E_2$  subunit and the other with a 78-bp deletion, thereby indicating that they were heterozygous for this mutation. The brother had a normal size mRNA, hence was homozygous of the normal allele.

#### Acknowledgments

We are indebted to Dr. Y. Kudo of Kumamoto City Hospital for provision of the peripheral leukocytes from the patient and her family members. Dr. J. Asaka (Shionogi Institute for Medical Science) and Dr. T. Kunisada (Department of Pathology Institute for Medical Immunology, Kumamoto University Medical School) provided the synthetic oligonucleotides. We also thank M. Ohara for helpful comments and M. Hayashi and M. Tsutsui for secretarial services.

This work was supported in part by grants from the Ministry of Education, Science, and Culture of Japan (62304042), and from the National Center of Neurology and Psychiatry of the Ministry of Health and Welfare, Japan (2–B).

#### References

1. Pettit, F. H., S. J. Yeaman, and L. J. Reed. 1978. Purification and characterization of branched chain  $\alpha$ -keto acid dehydrogenase complex of bovine kidney. *Proc. Natl. Acad. Sci. USA*. 75:4881-4885.

2. Danner, D. J., S. K. Lemmon, J. C. Besharse, and L. J. Elsas. 1979. Purification and characterization of branched chain  $\alpha$ -keto acid dehydrogenase from bovine liver mitochondria. J. Biol. Chem. 254:5522-5526.

3. Heffelfinger, S. C., E. T. Sewell, and D. J. Danner. 1983. Antibodies to bovine liver branched-chain 2-oxo acid dehydrogenase cross-react with this enzyme complex from other tissues and species. *Biochem. J.* 213:339-344.

 Chuang, D. T., C.-W. C. Hu, L. S. Ku, W.-L. Niu, D. E. Myers, and R. P. Cox. 1984. Catalytic and structural properties of the dihydrolipoyl transacylase component of bovine branched-chain α-keto acid dehydrogenase. J. Biol. Chem. 259:9277-9284.

 Odessey, R. 1982. Purification of rat kidney branched-chain oxo acid dehydrogenase complex with endogenous kinase activity. *Biochem. J.* 204:353–356. 6. Lau, K. S., H. R. Fatania, and P. J. Randle. 1982. Regulation of the branched chain 2-oxoacid dehydrogenase kinase reaction. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 144:57-62.

7. Paxton, R., and R. A. Harris. 1982. Isolation of rabbit liver branched chain  $\alpha$ -keto acid dehydrogenase and regulation by phosphorylation. J. Biol. Chem. 257:14433-14439.

8. Fatania, H. R., P. A. Patston, and P. J. Randle. 1983. Dephosphorylation and reactivation of phosphorylated purified ox-kidney branched-chain dehydrogenase complex by co-purified phosphatase. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 158:234-238.

9. Damuni, Z., M. L. Merryfield, J. S. Humphreys, and L. J. Reed. 1984. Purification and properties of branched-chain  $\alpha$ -keto acid dehydrogenase phosphatase from bovine kidney. *Proc. Natl. Acad. Sci. USA*. 81:4335–4338.

10. Cook, K. G., A. P. Bradford, and S. J. Yeaman. 1985. Resolution and reconstitution of bovine kidney branched-chain 2-oxo acid dehydrogenase complex. *Biochem. J.* 225:731-735.

11. Reed, L. J., and M. L. Hackert. 1990. Structure-function relationships in dihydrolipoamide acyltransferases. J. Biol. Chem. 265:8971-8974.

12. Tanaka, K., and L. E. Rosenberg. 1983. Disorders of branched chain amino acid and organic acid metabolism. *In* The Metabolic Basis of Inherited Disease. J. B. Stanbury, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, and M. S. Brown, editors. McGraw-Hill Inc., New York. 440–473.

13. Indo, Y., A. Kitano, F. Endo, I. Akaboshi, and I. Matsuda. 1987. Altered kinetic properties of the branched-chain  $\alpha$ -keto acid dehydrogenase complex due to mutation of the  $\beta$ -subunit of the branched-chain  $\alpha$ -keto acid decarboxylase (E<sub>1</sub>) component in lymphoblastoid cells derived from patients with maple syrup urine disease. J. Clin. Invest. 80:63-70.

14. Indo, Y., I. Akaboshi, Y. Nobukuni, F. Endo, and I. Matsuda. 1988. Maple syrup urine disease: a possible biochemical basis for the clinical heterogeneity. *Hum. Genet.* 80:6-10.

15. Danner, D. J., N. Armstrong, S. C. Heffelfinger, E. T. Sewell, J. H. Priest, and L. J. Elsas. 1985. Absence of branched chain acyl-transferase as a cause of maple syrup urine disease. *J. Clin. Invest.* 75:858-860.

16. Nobukuni, Y., H. Mitsubuchi, F. Endo, and I. Matsuda. 1989. Complete primary structure of the transacylase  $(E_2b)$  subunit of the human branched chain  $\alpha$ -keto acid dehydrogenase complex. *Biochem. Biophys. Res. Commun.* 161:1035-1041.

17. Danner, D. J., S. Litwer, W. J. Herring, and J. Pruckler. 1989. Construction and nucleotide sequence of a cDNA encoding the full-length preprotein for human branched chain acyltransferase. J. Biol. Chem. 264:7742-7746.

 Matsuda, I., J. Yamamoto, N. Nagata, N. Ninomiya, I. Akaboshi, H. Ohtsuka, and T. Katsuki. 1977. Lysosomal enzyme activities in cultured lymphoid cell lines. *Clin. Chim. Acta.* 80:483–486.

19. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.).* 227:680-685.

20. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanato-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.

21. Saiki, R. K., D. H. Gelfand, S. Stofeel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science (Wash. DC)*. 239:489–491.

22. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

23. Mount, S. M. 1982. A catalogue of splice junction sequences. *Nucleic Acids Res.* 10:459–472.

24. Vnencak-Jones, C. L., J. A. Phillips III, E. Y. Chen, and P. H. Seeburg. 1988. Molecular basis of human growth hormone gene deletions. *Proc. Natl. Acad. Sci. USA*. 85:5615–5619.

25. Schon, E. A., R. Rizzuto, C. T. Moraes, H. Nakase, M. Zeviani, and S. DiMauro. 1989. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. *Science (Wash. DC).* 244:346-349.

26. Efstratiadis, A., J. W. Posakony, T. Maniatis, R. M. Lawn, C. O'Connell, R. A. Spritz, J. K. DeRiel, B. G. Forget, S. M. Weissman, J. L. Slightom, et al. 1980. The structure and evolution of the human  $\beta$ -globin gene family. *Cell.* 21:653–668.

27. Lamond, A. I., M. M. Konarska, P. J. Grabowski, and P. A. Sharp. 1988. Spliceosome assembly involves the binding and release of U4 small nuclear ribonucleoprotein. *Proc. Natl. Acad. Sci. USA*. 85:411-415.

28. Treisman, R., S. H. Orkin, and T. Maniatis. 1983. Specific transcription and RNA splicing defects in five cloned  $\beta$ -thalassaemia genes. *Nature (Lond.)*. 302:591-596.

29. Baird, M., C. Driscoll, H. Schreiner, G. V. Sciarratta, G. Sansone, G. Niazi, F. Ramirez, and A. Bank. 1981. A nucleotide change at a splice and junction in the human  $\beta$ -globin gene is associated with  $\beta^{\circ}$ -thalassemia. *Proc. Natl. Acad. Sci. USA*. 78:4218-4221.

30. Marvit, J., A. G. DiLella, K. Brayton, F. D. Ledley, K. J. H. Robson, and S. L. C. Woo. 1987. GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria. *Nucleic Acids Res.* 15:5613–5628.